Modulation of human T-cell suppressor activity by beta endorphin and glycyl-L-glutamine

Endorphinergic Enhancement Attenuation of Post-traumatic Stress Disorder (PTSD) via Activation of Neuro-immunological Function in the Face of a Viral Pandemic

Introduction

Polymorphic gene variants, particularly the genetic determinants of low dopamine function (hypodopaminergia), are known to associate with Substance Use Disorder (SUD) and a predisposition to PTSD. Addiction research and molecular genetic applied technologies supported by the National Institutes of Health (NIH) have revealed the complex functions of brain reward circuitry and its crucial role in addiction and PTSD symptomatology.

Discussion

It is noteworthy that Israeli researchers compared mice with a normal immune system with mice lacking adaptive immunity and found that the incidence of PTSD increased several-fold. It is well established that raising endorphinergic function increases immune response significantly. Along these lines, Blum's work has shown that D-Phenylalanine (DPA), an enkephalinase inhibitor, increases brain endorphins in animal models and reduces stress in humans. Enkephalinase inhibition with DPA treats Post Traumatic Stress Disorder (PTSD) by restoring endorphin function. The Genetic Addiction Risk Severity (GARS) can characterize relevant phenotypes, genetic risk for stress vulnerability vs. resilience. GARS could be used to pre-test military enlistees for adaptive immunity or as part of PTSD management with customized neuronutrient supplementation upon return from deployment.

Conclusion

Based on GARS values, with particular emphasis on enhancing immunological function, pro-dopamine regulation may restore dopamine homeostasis. Recognition of the immune system as a "sixth sense" and assisting adaptive immunity with Precision Behavioral Management (PBM), accompanied by other supportive interventions and therapies, may shift the paradigm in treating stress disorders.

Cerebrospinal and plasma amino acid concentrations after administration of i.v. glycyl-glutamine and glycyl-tyrosine containing amino acid solutions in humans

BACKGROUND

Glycyl-glutamine and glycyl-tyrosine may supply adequate glutamine and tyrosine in amino acid solutions for parenteral nutrition. However, plasma peptides may be transported into the cerebrospinal fluid, exerting effects on the neuronal tissue. Cerebrospinal fluid (CSF) and plasma amino acid concentrations after administration of a glycyl-glutamine/glycyltyrosine supplemented amino acid solution were therefore evaluated in a randomized controlled comparison with a conventional amino acid infusion.

METHODS

Dipeptide/amino acid solutions (0.60 mL/h/kg; 82.2 mg total dipeptides/amino acids/h/kg) or conventional amino acid solutions (0.73 mL/h/kg; 83.2 mg total amino acids/h/kg) were infused in 15 patients per group scheduled to undergo spinal anesthesia for urologic surgery over a 12-hour period preoperatively. Plasma amino acids were measured before the infusion was started. CSF and venous concentrations were analyzed simultaneously before the infusion was stopped. CSF samples were drawn through the spinal needle for anesthesia.

RESULTS

The dipeptide-containing solution did not increase either dipeptide to detectable levels in the CSF (detection limit < 5.0 nmol/mL). Venous glycyl-glutamine increased from below detection limits up to 308 +/- 111 nmol/mL (p < .05), whereas glycyl-tyrosine could not be found. In the dipeptide group, venous glutamine and tyrosine were higher (p < .05) but only tyrosine appeared in small amounts (p < .05) in the cerebrospinal fluid.

CONCLUSIONS

This study provides no evidence to support a CSF entry of IV glycyl-tyrosine and glycyl-glutamine under conditions of a normal blood-brain barrier in the adult (detection limit 5 nmol/mL). The data suggest that amino acid solutions containing these dipeptides may be used in parenteral solutions for nutrition support.

Psychoneuroimmunology: stress effects on pathogenesis and immunity during infection

The mammalian response to stress involves the release of soluble products from the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis. Cells of the immune system respond to many of the hormones, neurotransmitters, and neuropeptides through specific receptors. The function of the immune system is critical in the mammalian response to infectious disease. A growing body of evidence identifies stress as a cofactor in infectious disease susceptibility and outcomes. It has been suggested that effects of stress on the immune system may mediate the relationship between stress and infectious disease. This article reviews recent psychoneuroimmunology literature exploring the effects of stress on the pathogenesis of, and immune response to, infectious disease in mammals.

Glycyl-L-glutamine antagonizes alpha-MSH-elicited thermogenesis

The objective of this study was to determine whether glycyl-L-glutamine [beta-endorphin(30-31)] modulates the thermoregulatory actions of alpha-MSH. Microinjection of alpha-MSH (0.06 nmol) into PGE2-responsive thermogenic sites in the medial preoptic area of rats generated a hyperthermic response, inducing a 0.85 +/- 0.19 degrees C rise in colonic temperature (Tc) within 45 min. Coadministration of glycyl-L-glutamine (3.0 nmol) completely blocked the response, maintaining Tc at baseline levels. This was not attributable to glycyl-L-glutamine hydrolysis because coadministration of glycine and glutamine had no effect on alpha-MSH-induced thermogenesis. Glycyl-L-glutamine, injected alone, was similarly without effect. These data indicate that glycyl-L-glutamine inhibits alpha-MSH-induced thermogenesis but is devoid of thermoregulatory activity itself.

Organ clearance of tyrosyl-arginine and its effect on amino acid metabolism in young sheep

In a long-term multiple-catheter sheep model (n = 5), organ clearance of the dipeptide tyrosyl-arginine (TyrArg) and its effects on interorgan amino acid metabolism were investigated. Clearance by hindlimb and splanchnic tissues was measured during infusion into the external iliac artery and superior mesenteric artery, respectively. The hindlimb, intestine, and total splanchnic region removed 32% +/- 9.2% (mean +/- SE), 23% +/- 15%, and 33% +/- 24%, respectively, of the amount of TyrArg infused. There was a large release of tyrosine and arginine when TyrArg was infused into either the hindlimb or intestine, which was quantitatively similar to the TyrArg taken up by these organs. However, across the total splanchnic region, the baseline influx of tyrosine and arginine was not altered by infusion of TyrArg. During either clearance study, only trace amounts of TyrArg or its constituent amino acids were excreted in urine. Infusion of TyrArg produced the following effects on interorgan amino acid metabolism: (1) a reduction in the initial efflux of phenylalanine, leucine, isoleucine, and valine from the hindlimb; (2) a reduction in net efflux of citrulline by the intestine and total splanchnic tissues; and (3) a reduction in efflux of arginine and uptake of citrulline from the kidney. In conclusion, we have shown that TyrArg is cleared from the bloodstream by hindlimb (predominantly muscle) and splanchnic tissues. These results indicate that TyrArg taken up by the hindlimb and intestine was hydrolyzed to its constituent amino acids, which were released quantitatively into the circulation. Of the tissues studied, only the liver appeared to use the amino acids liberated from hydrolysis of TyrArg.(ABSTRACT TRUNCATED AT 250 WORDS)

Immunosuppression in the definitive and intermediate hosts of the human parasite Schistosoma mansoni by release of immunoactive neuropeptides

Evidence supporting the concept that the parasitic trematode Schistosoma mansoni may escape immune reactions from its vertebrate (man) or invertebrate (the freshwater snail Biomphalaria glabrata) hosts by using signal molecules it has in common with these hosts was obtained by the following experiments. The presence of immunoactive proopiomelanocortin (POMC)-derived peptides [corticotropin (ACTH), beta-endorphin] in, and their release from, S. mansoni was demonstrated. Coincubation of adult worms with human polymorphonuclear leukocytes or B. glabrata immunocytes led to the appearance of alpha-melanotropin (MSH) in the medium. The conclusion that this alpha-MSH resulted from conversion of the parasite ACTH by neutral endopeptidase 24.11 (NEP) present on these cells was supported by the fact that the alpha-MSH level in the medium was markedly reduced by addition of the specific NEP inhibitor phosphoramidon. This interpretation is substantiated by the fact that no conversion was observed in comparable tests with human monocytes, which exhibit no NEP activity. alpha-MSH has the capacity to inactivate formerly active immunocytes not only from the definitive host (man, hamster) but also from the intermediate host (B. glabrata), as determined by microscopic computer-assisted examination of conformational changes. POMC-derived peptides have been detected in B. glabrata hemolymph 2, 10, and 24 days after infection by S. mansoni miracidia. Immunocytes from infected snails were found to be inactivated, and this inactivation was prevented by antibodies directed against ACTH and alpha-MSH. The immunoactive beta-endorphin released from S. mansoni does not appear to be subject to enzymatic conversion. Since it is active at lower concentrations, it may be used for distant signaling.

Magnetic fields, brain and immunity: effect on humoral and cell-mediated immune responses

Magnetic fields (MF) can influence biological systems in a wide range of animal species and humans. We report here on the influence of static MF, locally applied to the brain area, on immune system performances in the rat. In the first series of experiments two AKMA micromagnets (M) with the influx density of 600 Gauss were bilaterally implanted (with "N" polarity facing the cranial bones) and fixed to the skull posterior to the fronto-parietal suture (parietal brain exposure). Rats implanted with iron beads (I) and sham-operated (SO) rats served as controls. Animals were exposed to MF or I during different periods of time before and after immunization with several soluble or cellular antigens. We report here on the in vivo immunoregulating effects of centrally applied MF on plaque-forming cell (PFC) response, local hypersensitivity skin reactions and experimental allergic encephalomyelitis. The selective influence of MF applied to different brain regions on PFC response was evaluated, as well. For this purpose, two M were bilaterally implanted in the area of (a) frontal, (b) parietal and (c) occipital brain regions. Rats were under the influence of MF for 20 days before and 4 days after immunization with sheep red blood cells. Groups of nonimmunized rats were exposed for 14, 24 and 34 days to parietally implanted M or I, and the number of peripheral blood CD4+ and CD8+ cells determined by mouse anti-rat W3/25 and MRC OX 8 monoclonal antibodies. The results show an overall in vivo immunopotentiation of humoral and cell-mediated immune responses in rats exposed to MF. Furthermore, these immunomodulating effects of centrally applied MF depend on at least two basic parameters, time of exposure and brain region exposed. The highest immune performance was obtained after exposure of the occipital brain region for a total period of 24 days. The results provide further evidence of the complex interrelationship between the environment, the central nervous system and the immune system.

Beta-endorphin C-terminal peptide evokes arachidonic acid release from cortical neurones

The release of free [3H]arachidonic acid and its metabolites (AAM) from mouse embryo cortical neurones cultured in serum-free medium stimulated by beta-endorphin C-terminal dipeptide (glycl-L-glutamine, Gly-Gln) was investigated. Gly-Gln but not the related dipeptide, glycyl-glutamic acid, caused a 2-fold elevation of AAM release which was blocked in the absence of extracellular calcium, in the presence of 5 mM magnesium and by the phospholipase A2 (PLA2) inhibitor, mepacrine. Other proopiomelanocortin (POMC) peptides did not elicit AAM release. The response to Gly-Gln was unaffected by D-amino-2-phospho-5-valeric acid (AP5) and 7-chlorokynurenic acid (7-ClKY), antagonists respectively at the ligand and allosteric glycine binding sites of the NMDA glutamate receptor subtype. However, it was inhibited in a dose-dependent manner by antagonists at the phencyclidine (PCP) and sigma sites. The results suggest that Gly-Gln causes AAM release by activating PLA2 through the mediation of a PCP/sigma-like receptor.

Physiological basis for neuroimmunomodulation

A large number of clinical and experimental observations indicate that immune responses may be modulated by the central nervous system (CNS). The immune system (IS) and CNS are known to communicate via the endocrine and the autonomic nervous systems. In this overview, we will focus on the immunomodulating role of neurotransmitters and neuropeptides. Immune cells appear to express membrane antigens similar to those of neural cells. Similarities re-enforce analogies between CNS and IS cells. The concept that the CNS modulates immune functions implies that the immune system feeds back information to the CNS. In fact, interleukins have neuroendocrine functions whether they are produced at the periphery by immune cells or at the CNS level by glial cells. Finally, the possible endocrine functions of lymphocytes are described and it is suggested that a complete regulatory loop between immune and neuro-endocrine systems exists. Studies in neuro-immunomodulation are of great importance from a theoretical point of view, the CNS-IS inter-relationships may not be considered only between the CNS and the periphery but also at the level of the immune micro-environment which may be considered as an immune-neuro-endocrine complex.

The opioid specificity of beta-endorphin enhancement of murine lymphocyte proliferation

Beta-endorphin (beta-end) is a potent analgesic peptide which exhibits a variety of pharmacological activities in the central nervous system (CNS) following binding of its N-terminus to specific opioid receptors. Although C-terminal binding sites for this 31-amino-acid peptide have been characterized in CNS tissue, identification of their possible function has been facilitated by studies of beta-end effects on lymphocyte activities. In this communication, we report a detailed analysis of the opioid specificity of the ability of beta-end to enhance T cell mitogen-induced proliferation in unfractionated murine splenocytes. Intact 31-amino-acid beta-end peptides from several species, including human, camel and rat, enhanced concanavalin A-stimulated [3H]thymidine uptake 50-640% in a dose-dependent, naloxone-irreversible fashion. The presence of the C-terminal amino acids was required for the enhancement activity, since met-enkephalin, alpha- and gamma-endorphin, and human beta-end 1-27 were ineffective. Accordingly, the truncated peptides, human beta-end 6-31 and 18-31, were also able to enhance the Con A response. However, human beta-end 18-31 was consistently not as effective as beta-end 6-31 or the intact 31-residue peptide. These data suggest that although the C-terminus contains the primary active sequence, the N-terminus contributes to the overall potency of the effect. In support of this assertion, N-acetylation, which abolishes opioid binding activity, resulted in a reduced magnitude of enhancement. The data suggest that beta-end interacts with a non-opioid receptor which has specificity characteristics strikingly similar to non-opioid receptors characterized in CNS tissue.

Characteristics of beta-endorphin-induced histamine release from rat serosal mast cells. Comparison with neurotensin, dynorphin and compound 48/80

Rat peritoneal mast cells were exposed to the neurohormone and basic opioid peptide beta-endorphin. beta-Endorphin induced a dose-dependent release of histamine from the mast cells. A significant histamine release was found at 5 mumol/l of beta-endorphin and maximal release (35% of total) at 20 mumol/l. The histamine release process was very rapid and terminated within 30 s at 37 C, and in this sense is very similar to the histamine release induced by compound 48/80 or neurotensin. The histamine release was temperature-dependent showing an optimum release around 30 C, and it was independent of available extracellular calcium, but was inhibited in the presence of high extracellular calcium concentrations. Naloxone, only in very high concentrations (10 mmol/l), inhibited the release, and the very same concentration also inhibited the neurotensin - as well as the compound 48/80-induced histamine release. Cromoglycate and benzalkoniumchloride, a 48/80 antagonist, both produced a progressive dose-dependent inhibition of beta-endorphin-, neurotensin- as well as compound 48/80-induced histamine release. Taken together, the findings indicate that the opioid peptide beta-endorphin induces a selective, energy-dependent release of histamine from peritoneal rat mast cells. The pattern of release has much in common with that of compound 48/80 and other basic peptides, such as neurotensin and substance P. In addition this pattern of release is similar to that induced by dynorphin.

Effects of beta-endorphin on rat mast cells

The endogenous opioid peptide beta-endorphin induced a dose-dependent release of histamine from rat peritoneal mast cells. The threshold concentration was around 10(-6) M and the optimal concentration of 2 X 10(-5) M released 35% of the total histamine. The release of histamine was very rapid, complete within 10 s, and very similar to that induced by neurotensin or compound 40/80. The histamine release was temperature dependent and inhibited at increased extracellular calcium concentrations. Taken together, the findings indicate that the release of histamine induced by beta-endorphin is a specific, energy-dependent process. The pattern of release has much in common with that induced by other basic peptides, such as neurotensin, dynorphin and substance P.

Opioid peptides modulate immune functions. A review

In the past few years it has become evident that neuropeptides may be direct mediators in the modulation of the immune response and the unspecific defense by the brain. Lymphocytes have been thought to have opioid receptors and to respond to opioids with an increase in blastogenesis, cytotoxicity and factor release. Lymphocytes are said to release various neuropeptides. Furthermore, there are some unexplained effects of morphine on the immune system and of the immune system on morphine withdrawal. The purpose of this paper is to review what has been previously published in this field. The well established modulation of phagocyte functions by opioids will only be scanned.

Enkephalin activity on antigen-induced proliferation of human peripheral blood mononucleate cells

The effect of the two opioid pentapeptides met- and leu-enkephalin and of the tetrapeptide TYR-GLY-GLY-PHE on the stimulated proliferation of human peripheral blood mononucleate cells (PBMC) is described. Cell populations obtained from different donors were induced to proliferate with a Candida antigen. In the presence of the antigen, met-enkephalin and TYR-GLY-GLY-PHE had a concentration-dependent diphasic effect. The proliferation of PBMC was stimulated at high peptide concentration, while it was inhibited at the lower concentrations used. The effect of leu-enkephalin appears to be rather ambiguous, and directed towards the inhibition rather than the stimulation of PBMC proliferation.

Differential effects of beta-endorphin fragments on human natural killing

The endogenous opiate peptide, beta-endorphin, has two effects on human natural killing (NK). Preincubation of effector lymphocytes with between 10(-7) and 10(-11) M beta-endorphin increases NK. Preincubation with lower concentrations results in a reduction in NK. Endorphin peptides containing an unmodified N-terminal sequence, and which are known to bind only to opiate receptors, increase NK. Sequences reported to bind only to nonopiate receptors reduce NK.

Endogenous opiates: 1986

This is the ninth installment of our annual review of research involving the endogenous opiate peptides. It is restricted to the non-analgesic and behavioral studies of the opiate peptides published in 1986. The specific topics this year include stress; tolerance and dependence; eating; drinking; gastrointestinal, renal, and hepatic processes; mental illness; learning, memory, and reward; cardiovascular responses; respiration and thermoregulation; seizures and other neurological disorders; activity; sex, pregnancy, and development; and some other behaviors.

Physical dependence to morphine diminishes the interferon response in mice

Morphine pellet implantation in mice was demonstrated to diminish resistance to encephalomyocarditis virus infections. The variations in the response to three different interferon (IFN) inducers--Newcastle disease virus, Escherichia coli lipopolysaccharide and a tilorone analogue--were evaluated. A close relationship between morphine dependence and IFN response was detected. A clear inhibition in IFN induction appeared as a concomitant phenomenon with the syndrome of morphine dependence. In the response intensity, the mice strain tested was more important than the total drug dose in the pellet. This effect of morphine on IFN responses presented a characteristic age-related pattern and, perhaps, may also be influenced by the H-2 murine phenotype.

Endorphinergic modulation of immune function: potent action of the dipeptide glycyl-L-glutamine

Glycyl-L-glutamine (GLG), the carboxy terminal dipeptide of B-endorphin, inhibits brainstem neuronal activity. It also occurs along with B-endorphin in pituitary secretory vesicles suggesting a neurosecretory role for this dipeptide. We have evaluated potential immunoregulatory actions of this compound using the Phytohemaglutinin (PHA) blastogenesis and the concanavalin A (ConA) suppressor cell induction assays. GLG in low doses (10(-12) M) enhanced the response of human lymphocytes to PHA induced blastogenesis, however; with higher doses of the dipeptide (10(-7) M) immunosuppression was consistently observed. In the suppressor cell induction assay, when GLG was used together with ConA, we observed a dose-dependent inhibition of suppressor activity. These results clearly indicate that GLG produces a dose dependent bidirectional modulation of at least two indicies of immune function, and confirm the presence of a second pituitary peptide with the potential for potent immunomodulatory action.